Cytheris SA, a privately held clinical-stage biopharmaceutical company with headquarters in a suburb of Paris, France, is focused on research and development of new therapies for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial infections such as HIV, HCV, and HBV or lympho-depleting treatments such as chemotherapy, radiotherapy, bone marrow transplantation (BMT) and hematopoietic cell transplantation (HCT).

The company’s lead compound, recombinant human Interleukin-7 (r-hIL-7), is a critical growth factor for immune T cell recovery and enhancement. Cytheris is currently conducting multiple international clinical studies of IL-7 in HIV, HBV, HCV and cancer.